CVS Health stock price continued to underperform the market this year as the pharmacy industry faced significant challenges. It has dropped by over 30% this year, while the S&P 500 and Nasdaq 100 indices have soared to a record high.
The persistently elevated utilization of medical services is significantly putting pressure on CVS Health's Health Care Benefits segment.
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
CVS Health (CVS) reported earnings 30 days ago. What's next for the stock?
CNBC's Jim Cramer explains why he is keeping an eye on shares of CVS Health.
Shares of healthcare giant CVS Health Corp (NYSE:CVS) are 1.5% higher before the bell, after a bull note at Deutsche Bank.
Deutsche Bank analyst George Hill upgraded CVS Health to Buy from Hold with an unchanged price target of $66. The firm believes both the company's earnings and multiple are now likely near trough levels. CVS has taken steps to turn the company towards improving profitability, the analyst tells investors in a research note. Following an analysis of the managed care segment, Deutsche thinks an earnings recovery is both achievable and will outpace Street expectations.
CVS Health (CVS -0.18%) has been a long-running migraine for shareholders, struggling to manage rising medical costs that have impacted profitability. At the time of writing, the stock is down 25% year to date and more than 40% lower than its record-high price of $101.29 set in February 2022.
Recently, Zacks.com users have been paying close attention to CVS Health (CVS). This makes it worthwhile to examine what the stock has in store.
Israel "Izzy" Englander's net worth tops $14 billion. He doesn't need dividend income.
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.